Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > TAR-200 and other

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Jan 04, 2024 5:23pm

222 Views

Post# 35811401

RE:RE:RE:TAR-200 and other

Nice chart, but I was using a December 5th article on 30 patients and they mentioned same 6 patients from May which had reached 12 months CR duration. https://www.urologytimes.com/view/fda-grants-tar-200-breakthrough-therapy-designation-for-bcg-unresponsive-nmibc

DJDawg wrote:
My read was from the swimmers plot in this link Enrique.

https://www.urotoday.com/conference-highlights/esmo-2023/esmo-2023-bladder-cancer/147563-esmo-2023-results-from-sunrise-1-in-patients-with-bacillus-calmette-guerin-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer-hr-nmibc-receiving-tar-200-monotherapy.html

From Oct 2023.

Looks like an evolving CR rate at 12m to me. Looks better than 20% CR at 12m to me but I'm happy to be wrong.